

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

## EQA round: AP2/21 - Antithrombotic Agents

Deadline: 17.09.2021

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>Set 1</b>														
<b>(108) Apixaban</b>					30							30	26	87%
Samples and groups	[µg/L]													
<b>Sample A1</b>		266	26	9,6	30	CVP	266	11	25%	199	333	30	29	97%
(2) Chromogenous substrat		266	26	9,6	30	0						30		
<b>Sample B1</b>		65,5	6,4	9,8	30	CVP	65,5	2,9	25%	49,1	81,9	30	26	87%
(2) Chromogenous substrat		65,5	6,4	9,8	30	0						30		
<b>Set 2</b>														
<b>(109) Dabigatran</b>					33							33	30	91%
Samples and groups	[µg/L]													
<b>Sample A2</b>		206	24	12	33	CVP	206	10	25%	154	258	33	32	97%
(1) Coagulometer		210	28	13	24	0						24		
(2) Chromogenous substrat		196	10	5,3	9	0						9		
<b>Sample B2</b>		50,3	5,1	10	33	CVP	50,3	2,2	25%	37,7	62,9	33	30	91%
(1) Coagulometer		51,7	6,0	12	24	0						24		
(2) Chromogenous substrat		48,3	2,0	4,1	9	0						9		
<b>Set 3</b>														
<b>(110) Rivaroxaban</b>					37							37	34	92%
Samples and groups	[µg/L]													
<b>Sample A3</b>		313	27	8,7	37	CVP	313	11	25%	234	392	37	36	97%
(2) Chromogenous substrat		313	27	8,7	37	1						37		
<b>Sample B3</b>		73,1	5,3	7,3	37	CVP	73,1	2,2	25%	54,8	91,4	37	34	92%
(2) Chromogenous substrat		73,1	5,3	7,3	37	1						37		

st\_kn\_p

End of report

Printed: 30.09.2021